In 2023, beta-blocking medicine sales in Canada were at $206.0 million. From 2024 to 2028, forecasts show a gradual decline in sales values from $204.6 million to $199.4 million. This reflects a negative year-on-year growth, with sales declining 0.8% from 2024 to 2025, 0.7% from 2025 to 2026, 0.6% from 2026 to 2027, and 0.4% from 2027 to 2028. The compound annual growth rate (CAGR) for 2024–2028 is estimated at -0.6%.

Future trends to watch for:

Potential shifts in healthcare policies that could affect prescription patterns.
Advancements in alternative cardiovascular treatments that may impact beta-blocker demand.
Demographic changes, such as an aging population, which could influence healthcare needs.

Download as XLS

More about Beta-Blocker Industry 2025-2029